Somewhat Favorable News Coverage Somewhat Unlikely to Affect Array BioPharma (ARRY) Share Price
Media headlines about Array BioPharma (NASDAQ:ARRY) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Array BioPharma earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.653384155289 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Array BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its 2.625% Conv… (ih.advfn.com)
- Array BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its 2.625% Convertible Senior Notes due 2024 and Shares of its Common Stock (finance.yahoo.com)
- Array BioPharma Inc. (ARRY) and Discover Financial Services (DFS) Insider Investors Have Active Stake – Wallstreet Investorplace (wallstreetinvestorplace.com)
- What Are Analysts Report About Array BioPharma Inc. (ARRY) – Newsline (newsline.com)
- Have a grip on these -:- Array BioPharma Inc. (NASDAQ:ARRY), KBR, Inc. (NYSE:KBR), Radius Health, Inc. (NASDAQ … – Market Breaking Point (press release) (journalfinance.net)
A number of analysts have recently commented on ARRY shares. Piper Jaffray Companies reissued a “buy” rating and issued a $14.00 price objective on shares of Array BioPharma in a research report on Thursday, August 10th. Cantor Fitzgerald set a $13.00 price target on shares of Array BioPharma and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 price target on shares of Array BioPharma in a research report on Thursday, August 10th. Jefferies Group LLC set a $9.00 price target on shares of Array BioPharma and gave the stock a “buy” rating in a research report on Friday, August 25th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and set a $14.00 price target on shares of Array BioPharma in a research report on Monday, September 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $13.65.
Array BioPharma (ARRY) traded up $0.02 during trading hours on Thursday, hitting $11.18. 3,384,818 shares of the company’s stock traded hands, compared to its average volume of 3,912,146. Array BioPharma has a 12-month low of $6.73 and a 12-month high of $13.40. The company has a debt-to-equity ratio of 0.54, a quick ratio of 5.43 and a current ratio of 5.43.
Array BioPharma (NASDAQ:ARRY) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.22). Array BioPharma had a negative net margin of 127.73% and a negative return on equity of 127.87%. The firm had revenue of $29.75 million for the quarter, compared to the consensus estimate of $33.74 million. During the same period in the previous year, the company earned ($0.20) earnings per share. The company’s quarterly revenue was down 24.2% on a year-over-year basis. analysts predict that Array BioPharma will post -0.99 earnings per share for the current fiscal year.
In other Array BioPharma news, Director Kyle Lefkoff sold 38,865 shares of the company’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $12.31, for a total value of $478,428.15. Following the transaction, the director now directly owns 51,585 shares in the company, valued at $635,011.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.18% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-array-biopharma-arry-share-price/1708268.html.
About Array BioPharma
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.